OverviewSuggest Edit

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, companion diagnostics intended to direct a compound in development to the population that is most likely to benefit from its use.
TypePublic
Founded2009
HQBoulder, CO, US
Websiteclovisoncology.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Feb 2020)484(+4%)
Revenue (FY, 2019)$143 M(+50%)
Share Price (Jan 2021)$5.6 (-6%)
Cybersecurity ratingBMore

Key People/Management at Clovis Oncology

Ann Bozeman

Ann Bozeman

Executive Vice President of Human Resources
Robert W. Azelby

Robert W. Azelby

Director
Paul E. Gross

Paul E. Gross

Executive Vice President and General Counsel
James C. Blair

James C. Blair

Director
Gillian C. Ivers-Read

Gillian C. Ivers-Read

Executive Vice President and Chief Regulatory Officer
Richard A. Fair

Richard A. Fair

Director
Show more

Clovis Oncology Office Locations

Clovis Oncology has offices in Boulder, Oakland, San Francisco, Paris and in 6 other locations
Boulder, CO, US (HQ)
5500 Flatiron Pkwy #100
Oakland, CA, US
1330 Broadway floor 10
San Francisco, CA, US
499 Illinois St #230, San Francisco
Paris, FR
19 Boulevard Malesherbes
München, DE
Theatinerstraße 11/8th floor
Milano, IT
Via Monte di Pietà, 1
Show all (11)

Clovis Oncology Financials and Metrics

Clovis Oncology Revenue

Clovis Oncology's revenue was reported to be $143.01 m in FY, 2019
USD

Revenue (Q3, 2020)

38.8m

Net income (Q3, 2020)

(78.7m)

EBIT (Q3, 2020)

(72.5m)

Market capitalization (15-Jan-2021)

577.2m

Closing stock price (15-Jan-2021)

5.6

Cash (30-Sept-2020)

224.7m

EV

857.7m
Clovis Oncology's current market capitalization is $577.2 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

13.6m78.0k55.5m95.4m143.0m

Revenue growth, %

(100%)

General and administrative expense

10.6m16.6m21.5m30.5m40.7m138.9m175.8m182.8m

R&D expense

58.9m66.5m137.7m269.3m251.1m142.5m231.3m283.1m
Quarterly
USDQ1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

7.0m14.6m16.8m18.5m22.8m33.1m33.0m37.6m42.6m39.9m38.8m

Cost of goods sold

4.0m4.5m4.8m

Gross profit

14.5m18.0m

Gross profit Margin, %

78%79%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

144.1m323.2m482.7m278.8m216.2m464.2m221.9m161.8m

Accounts Receivable

121.0k6.2m12.9m20.6m

Prepaid Expenses

659.0k976.0k3.8m3.4m1.6m3.6m3.9m

Inventories

27.5m27.1m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

121.0m176.9m162.5m129.6m372.2m356.6m303.7m273.2m516.6m291.5m236.3m355.4m220.4m228.4m243.7m276.0m491.8m611.5m374.1m468.3m290.9m123.3m108.6m201.5m163.3m261.4m224.7m

Accounts Receivable

2.4m1.1m12.9m12.3m14.5m16.1m15.4m16.8m25.1m18.2m20.3m

Prepaid Expenses

650.0k419.0k378.0k524.0k605.0k1.2m866.0k581.0k2.2m3.1m3.1m2.4m10.4m14.5m7.4m5.5m4.9m2.9m4.6m2.7m2.9m3.8m3.5m4.6m2.7m1.8m3.4m

Inventories

6.5m6.5m5.3m69.2m63.0m43.7m25.0m26.9m
USDQ1, 2012

Financial Leverage

1.1 x
Show all financial metrics

Clovis Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Clovis Oncology Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Clovis Oncology Online and Social Media Presence

Embed Graph

Clovis Oncology Blogs

Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial

Trial to Evaluate the Combination of Rubraca ® (rucaparib) and OPDIVO ® (nivolumab) in Patients with Advanced Ovarian Cancer BOULDER, Colo. --(BUSINESS WIRE)--Aug. 8, 2018-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the randomization of the first patient in the Phase 3 ATHENA trial

Clovis Oncology Announces Second Quarter 2018 Operating Results

$23.8M in Rubraca ® sales for the second quarter of 2018 compared to $14.6M for Q2 2017 Rubraca approved in U.S. on April 6, 2018 for expanded ovarian cancer maintenance treatment indication Rubraca granted Marketing Authorization by European Commission on May 29 for treatment of recurrent ovarian

Q2 2018 Clovis Oncology, Inc. Earnings Conference Call

Q2 2018 Clovis Oncology, Inc. Earnings Conference Call marco.guevara@… Wed, 07/18/2018 - 11:01 Q2 2018 Clovis Oncology, Inc. Earnings Conference Call Display "add to calendar" true Event Type Earnings Conference Call Click her…

Clovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1

BOULDER, Colo. --(BUSINESS WIRE)--Jul. 18, 2018-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2018 financial results on Wednesday, August 1, 2018 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast

Clovis Oncology Frequently Asked Questions

  • When was Clovis Oncology founded?

    Clovis Oncology was founded in 2009.

  • Who are Clovis Oncology key executives?

    Clovis Oncology's key executives are Ann Bozeman, Robert W. Azelby and Paul E. Gross.

  • How many employees does Clovis Oncology have?

    Clovis Oncology has 484 employees.

  • What is Clovis Oncology revenue?

    Latest Clovis Oncology annual revenue is $143 m.

  • What is Clovis Oncology revenue per employee?

    Latest Clovis Oncology revenue per employee is $295.5 k.

  • Who are Clovis Oncology competitors?

    Competitors of Clovis Oncology include Northwest Biotherapeutics, Infinity Pharmaceuticals and Merrimack Pharmaceuticals.

  • Where is Clovis Oncology headquarters?

    Clovis Oncology headquarters is located at 5500 Flatiron Pkwy #100, Boulder.

  • Where are Clovis Oncology offices?

    Clovis Oncology has offices in Boulder, Oakland, San Francisco, Paris and in 6 other locations.

  • How many offices does Clovis Oncology have?

    Clovis Oncology has 11 offices.